When One Treatment Stops Working: New Approach Presented for Severe Inflammatory Bowel Diseases

A new study presented at the Digestive Disease Week 2026 suggests that combination therapy may significantly improve treatment outcomes for patients with inflammatory bowel diseases, especially those who have run out of effective treatment options, according to MedicalXpress.

The study focused on patients with Crohn's disease and ulcerative colitis — chronic inflammatory conditions that often become difficult to treat in advanced stages. In such patients, each subsequent therapy typically becomes less effective, leaving increasingly limited treatment options.

Researchers investigated a new strategy based on simultaneously targeting two different inflammatory mechanisms. The approach used a fixed-dose combination drug containing two antibodies, each designed to block a separate inflammatory pathway.

The results showed that combining two mechanisms of action produced a stronger effect than using either drug alone. Patients who had stopped responding to previous therapies experienced improvements in clinical indicators, including reduced disease activity and signs of remission.

Importantly, the increased effectiveness was not associated with a noticeable rise in the risk of side effects. Researchers noted that the safety profile remained comparable to that of the individual therapies.

The authors emphasized that one of the major challenges in treating these patients is the gradual “exhaustion” of standard treatment regimens, as the immune system finds alternative pathways to sustain inflammation. The combination approach aims to block several of these pathways at once, effectively “outsmarting” the disease.

The study is considered an important step toward more personalized treatment strategies for severe inflammatory bowel diseases, particularly for patients with treatment-resistant forms of the disease.

Follow NEWS.am Medicine on Facebook and Twitter